Kymera Therapeutics (KYMR) News Today $40.66 +1.52 (+3.88%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)State Street Corp decreased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,728,144 shares of the company's stock after selling 182,547 shares duringDecember 17, 2024 | marketbeat.comBTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy RecommendationDecember 11, 2024 | msn.comKymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG ResearchBTIG Research started coverage on Kymera Therapeutics in a research report on Tuesday. They set a "buy" rating and a $60.00 price objective on the stock.December 10, 2024 | marketbeat.comPositive Report for Kymera Therapeutics (KYMR) from Wells FargoDecember 9, 2024 | markets.businessinsider.comWellington Management Group LLP Has $218.59 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Wellington Management Group LLP boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,618,359 shares of the comDecember 9, 2024 | marketbeat.comTwo Sigma Advisers LP Sells 30,700 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Two Sigma Advisers LP cut its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 336,300 shares of the company's stock after sellingDecember 9, 2024 | marketbeat.comBMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform RecommendationDecember 6, 2024 | msn.comBMO Capital Markets Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR)BMO Capital Markets started coverage on shares of Kymera Therapeutics in a report on Friday. They issued a "market perform" rating and a $55.00 target price for the company.December 6, 2024 | marketbeat.comKymera Therapeutics initiated with a Market Perform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comCautious Optimism for Kymera Therapeutics: Hold Rating Amid Uncertainties in Innovative Protein Degradation ProgramsDecember 6, 2024 | markets.businessinsider.comKymera Therapeutics, Inc. (NASDAQ:KYMR) is Redmile Group LLC's 5th Largest PositionRedmile Group LLC lessened its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,393,256 shares of the company's stockDecember 5, 2024 | marketbeat.com25,000 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by Bamco Inc. NYBamco Inc. NY acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 25,000 shares of the company's stock, valued at approximately $1,183,000. A number of other institDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Makes New $1.32 Million Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Erste Asset Management GmbH acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,000 shares oDecember 4, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by BrokeragesKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, twelve have isDecember 4, 2024 | marketbeat.com12,743 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by HighVista Strategies LLCHighVista Strategies LLC bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,743 shares of theDecember 3, 2024 | marketbeat.comCinctive Capital Management LP Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Cinctive Capital Management LP purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 56,801 shares of the company's stock, valued at apprDecember 3, 2024 | marketbeat.comKymera Therapeutics upgraded to Overweight from Equal Weight at Wells FargoDecember 3, 2024 | markets.businessinsider.comWells Fargo Upgrades Kymera Therapeutics (KYMR)December 3, 2024 | msn.comFred Alger Management LLC Makes New $859,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Fred Alger Management LLC purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,141 shares of the company's stDecember 2, 2024 | marketbeat.comFmr LLC Has $241.82 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Fmr LLC grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,109,141 shares of the company's stock after acquiring an additional 282,301 shares durDecember 2, 2024 | marketbeat.comIntech Investment Management LLC Makes New $650,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Intech Investment Management LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,727 shares of the company's stock, valued at approximatelyDecember 1, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by Eventide Asset Management LLCEventide Asset Management LLC increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 507,902 shares of the company'November 29, 2024 | marketbeat.comNatixis Advisors LLC Purchases Shares of 14,378 Kymera Therapeutics, Inc. (NASDAQ:KYMR)Natixis Advisors LLC acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,378 shares of the company's stock, valuedNovember 28, 2024 | marketbeat.comKymera Therapeutics to Participate in Upcoming December Investor ConferencesNovember 26, 2024 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA grew its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 453,377 shares of thNovember 26, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by Jennison Associates LLCJennison Associates LLC boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 85.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 797,681 shares of the companNovember 22, 2024 | marketbeat.comStephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight RecommendationNovember 20, 2024 | msn.comKymera Therapeutics (NASDAQ:KYMR) Now Covered by StephensStephens assumed coverage on shares of Kymera Therapeutics in a research report on Monday. They issued an "overweight" rating and a $65.00 target price for the company.November 18, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7% - Here's What HappenedKymera Therapeutics (NASDAQ:KYMR) Trading Down 6.7% - Should You Sell?November 15, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, ten have aNovember 9, 2024 | marketbeat.comKymera Therapeutics price target raised to $49 from $45 at Morgan StanleyNovember 7, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)November 6, 2024 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00Morgan Stanley upped their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research note on Wednesday.November 6, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comKymera Therapeutics to Participate in Upcoming November Investor ConferencesNovember 5, 2024 | globenewswire.comUBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock PriceUBS Group lowered their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a report on Monday.November 4, 2024 | marketbeat.comFY2024 Earnings Estimate for KYMR Issued By Leerink PartnrsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now expects that the companyNovember 4, 2024 | marketbeat.comKymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call TranscriptNovember 3, 2024 | seekingalpha.comKymera Therapeutics: Promising Immunology Pipeline and Strategic Focus on KT-621 and KT-474 ProgramsNovember 3, 2024 | markets.businessinsider.comKymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...November 1, 2024 | uk.finance.yahoo.comKymera Therapeutics Reports Q3 2024 Earnings and Strategic ShiftNovember 1, 2024 | markets.businessinsider.comKymera Therapeutics (KYMR) Gets a Buy from Truist FinancialNovember 1, 2024 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst SaysGuggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday.November 1, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSKymera Therapeutics (NASDAQ:KYMR - Get Free Report) released its earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm's revenue for the quarter was down 20.9% compared to the same quarter last year. During the same period last year, the business earned ($0.90) earnings per share.November 1, 2024 | marketbeat.comKymera Therapeutics' (KYMR) "Buy" Rating Reiterated at Truist FinancialTruist Financial restated a "buy" rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday.November 1, 2024 | marketbeat.comKymera Therapeutics: Strategic Focus and Promising Trials Justify Buy RatingNovember 1, 2024 | markets.businessinsider.comKymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of EarningsOctober 31, 2024 | finance.yahoo.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - Time to Sell?Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - Time to Sell?October 31, 2024 | marketbeat.comInsights Ahead: Kymera Therapeutics's Quarterly EarningsOctober 31, 2024 | benzinga.comKymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateOctober 31, 2024 | globenewswire.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼1.670.60▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼15▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News Today ITCI News Today ROIV News Today ASND News Today RVMD News Today LNTH News Today NUVL News Today BPMC News Today LEGN News Today ELAN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYMR Stock Alerts